Patent · US Active

Paclitaxel enhancer compounds

US7671092B2 · kind B2 · utility

11Cited by

36References

5Claims

0Family size

Assignee

Synta Pharmaceuticals Corp. · US

Inventors

Keizo Koya · Sharon, US
Lijun Sun · Harvard, US
Shoujun Chen · Bedford, US
Noriaki Tatsuta · Lexington, US
Yaming Wu · Shanghai, CN
Mitsunori Ono · Lexington, US

Key dates

Filing date	Jan 18, 2008
Grant date	Mar 2, 2010
Priority date	—
Expiry date	Jan 18, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a compound represented by the Structural Formula (I): Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.